Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report

26.04.2024

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2024, which covers the results of its business activities for the first three months of 2024.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2024 amounted to CHF 260 mn (loss of CHF 254 mn in the same period 2023). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2024, is available under report.bbbiotech.ch/Q124 or www.bbbiotech.com.

 

Für weitere Informationen:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch